证券代码：603233 证券简称：大参林 公告编号：2025-036 大参林医药集团股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 减持期间 2025 年 6 月 27 日～2025 年 9 月 26 日 拟减持股份来源 IPO 前取得，其他方式取得 拟减持原因 调整资产和融资结构，偿还个人债务，降低股票质押率 预披露期间，若公司股票发生停牌情形的，实际开始减持的时间根据停牌时间相应顺延。 (一)相关股东是否有其他安排 □是 √否 (二)大股东及董监高此前对持股比例、持股数量、持股期限、减持方式、减持数 量、减持价格等是否作出承诺 √是 □否 （1）柯云峰、柯康保、柯金龙、柯舟、邹朝珠、梁小玲、王春婵、柯秀容 承诺：自发行人的股票上市之日起三十六个月内，不转让或者委托他人管理本人 直接和间接持有的发行人股份，也不由发行人回购该等股份。 （2）柯云峰、柯康 保、柯金龙同时承诺：在上述锁定期满后 12 个月内，减持公司股票数量不超过 其各自持有公司股份总数 ...

大参林医药集团股份有限公司 证券代码：603233 证券简称：大参林 公告编号：2025-036 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上述减持主体存在一致行动人： 1 一、减持主体的基本情况 股东名称 柯金龙 股东身份 控股股东、实控人及一致行动人 √是 □否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他：无 持股数量 229,631,849股 持股比例 20.16% 当前持股股份来源 IPO 前取得：85,185,129股 其他方式取得：144,446,720股 大股东及董监高持股的基本情况：截至本减持股份计划公告日，公司 实际控制人之一柯金龙持有公司股份 229,631,849 股，占公司总股本 比例为 20.16%。 减持计划的主要内容：为调整资产和融资结构，偿还个人债务，降低 股票质押率，股东柯金龙拟通过大宗交易减持其持有的公司股份不超 过 22,776,957 股，即不超过公司总股本的 2%。若公司于拟减持期间 ...

Group 1 - The actual controller of the company, Ke Jinlong, plans to reduce his holdings through block trading by up to 22.777 million shares, which accounts for no more than 2% of the company's total share capital [1]

| 证券代码：603233 | 证券简称：大参林 | 公告编号：2025-035 | | --- | --- | --- | | 债券代码：113605 | 债券简称：大参转债 | | 大参林医药集团股份有限公司 关于实施 2024 年度权益分派时"大参转债"停止转股的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因公司实施 2024 年度权益分派,本公司的相关证券停复牌情况如下： | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 113605 | 大参转债 | 可转债转股停牌 | 2025/6/11 | | | | 一、权益分派的基本情况 2025 年 5 月 20 日，公司召开了 2024 年年度股东大会，审议通过了《关于 2024 年度利润分配方案的议案》，拟以实施权益分派股权登记日的总股本扣减回购部分 的股份为基数分配利润 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company is experiencing stable revenue growth, with a profit turning point already evident [1] - Revenue forecasts for 2025-2027 have been adjusted downwards, while net profit estimates have been revised upwards [2] - The target price is set at 19.74 CNY, based on a PE valuation of 21X for 2025 [2] Financial Performance Summary - For 2023, the company achieved a revenue of 24,531 million CNY, with a year-on-year growth of 15.5% [4] - The projected revenues for 2024, 2025, 2026, and 2027 are 26,497 million CNY, 29,649 million CNY, 33,012 million CNY, and 36,383 million CNY respectively, with growth rates of 8.0%, 11.9%, 11.3%, and 10.2% [4] - The company's net profit attributable to the parent company for 2023 was 1,166 million CNY, with a projected increase to 1,073 million CNY in 2025 [4] - The gross margin is expected to stabilize around 35% in the coming years, with a slight decrease in 2024 [4] Business Expansion and Strategy - The company continues to expand its retail business, with a significant increase in the number of stores, including 907 new self-built stores and 420 acquired stores in 2024 [9] - The retail business generated 219.2 billion CNY in 2024, accounting for 82.7% of total revenue, with a gross margin of 36.6% [9] - The company is actively developing its new retail business, achieving an 80.4% coverage rate for O2O delivery services by the end of 2024 [9]

Investment Rating - The report maintains a "Buy" rating for the company [2][5] Core Views - The company is experiencing stable revenue growth, with a profit turning point already evident [1] - Revenue forecasts for 2025-2027 have been adjusted downwards, while sales expense ratios have been increased, predicting net profits of 1.073 billion, 1.247 billion, and 1.395 billion yuan respectively for those years [2] Financial Performance Summary - **Revenue**: - 2023A: 24.531 billion yuan, 2024A: 26.497 billion yuan (YoY +8.0%), 2025E: 29.649 billion yuan (YoY +11.9%) [4] - **Net Profit**: - 2023A: 1.166 billion yuan, 2024A: 915 million yuan (YoY -21.6%), 2025E: 1.073 billion yuan (YoY +17.3%) [4] - **Earnings Per Share**: - 2023A: 1.02 yuan, 2024A: 0.80 yuan, 2025E: 0.94 yuan [4] - **Gross Margin**: - 2023A: 35.9%, 2024A: 34.3%, 2025E: 35.0% [4] - **Net Margin**: - 2023A: 4.8%, 2024A: 3.5%, 2025E: 3.6% [4] - **Return on Equity**: - 2023A: 17.9%, 2024A: 13.3%, 2025E: 14.3% [4] Business Expansion and Strategy - The company opened 907 new self-built stores and acquired 420 stores in 2024, with a total of 16,553 stores by the end of the year [9] - Retail business revenue reached 219.2 billion yuan in 2024, driven by the expansion of direct-operated stores and new openings [9] - The company is actively developing new retail business, achieving an 80.4% coverage rate for O2O delivery services by the end of 2024 [9]

Group 1 - The company will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 6, 2025, from 15:00 to 16:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [1][2] - Investors can submit questions for the briefing from May 29, 2025, to June 5, 2025, before 16:00 [3] Group 2 - Key participants in the briefing will include the General Manager, the Secretary of the Board, the Chief Financial Officer, and an Independent Director [2] - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [2] - After the briefing, investors can view the main content and outcomes of the event on the Shanghai Stock Exchange Roadshow Center website [3]

Core Points - The employee stock ownership plan (ESOP) of Dazhenglin Pharmaceutical Group Co., Ltd. will expire on December 3, 2025 [1][2] - The ESOP was approved at the fourth extraordinary general meeting of shareholders in 2020 and has a duration of 36 months [1] - The board of directors has approved an extension of the ESOP for an additional 12 months, now set to expire on December 3, 2025 [2] Summary of Employee Stock Ownership Plan - The ESOP currently holds 6,572,239 shares, representing 0.58% of the company's total share capital [2] - The company has adhered to market trading rules and regulations during the ESOP period, ensuring no insider trading occurred [2] - Upon expiration of the ESOP, it will terminate automatically, and the management committee will handle the disposal of remaining rights in accordance with relevant regulations [2]

Core Viewpoint - The company has provided a guarantee of 600 million RMB for its subsidiaries to secure bank credit facilities, which is expected to support their operational needs and promote sustainable development [1][4]. Summary by Sections Guarantee Overview - The total guarantee amount provided by the company for its subsidiaries is 60,000 million RMB [1]. - The guarantee is a joint liability guarantee without any counter-guarantee [1]. - There are no overdue guarantees reported [1]. Subsidiary Information - The subsidiaries involved in the guarantee include: - Xinjiang Kangzhiyuan Pharmaceutical Co., Ltd. with a guarantee of 6,000 million RMB [1]. - Yili Kangzhiyuan Pharmaceutical Chain Co., Ltd. with a guarantee of 6,000 million RMB [1]. - Luoyang Dacarelin Pharmaceutical Co., Ltd. with a guarantee of 5,000 million RMB [1]. - Yingkou Fujuhe Pharmaceutical Chain Co., Ltd. with a guarantee of 3,000 million RMB [1]. - Xuchang Dacarelin Baoyuantang Pharmacy Chain Co., Ltd. with a guarantee of 2,000 million RMB [1]. - Maoming Dacarelin Chain Pharmacy Co., Ltd. with a guarantee of 27,000 million RMB [1]. - Xinyang Dacarelin Baixingfu Pharmaceutical Chain Co., Ltd. with a guarantee of 6,000 million RMB [1]. Financial Health of Subsidiaries - The subsidiaries have shown stable financial conditions, with total assets and liabilities as follows: - Xinjiang Kangzhiyuan: Total assets of 223.76 million RMB, liabilities of 200.03 million RMB, and net profit of 4.60 million RMB [2]. - Yili Kangzhiyuan: Total assets of 223.25 million RMB, liabilities of 175.11 million RMB, and net profit of 4.91 million RMB [2]. - Luoyang Dacarelin: Total assets of 408.73 million RMB, liabilities of 257.37 million RMB, and net profit of 14.47 million RMB [2]. - Yingkou Fujuhe: Total assets of 78.20 million RMB, liabilities of 49.33 million RMB, and net profit of 1.13 million RMB [2]. - Xuchang Dacarelin: Total assets of 90.55 million RMB, liabilities of 67.47 million RMB, and net profit of 1.37 million RMB [2]. - Maoming Dacarelin: Total assets of 1,992.40 million RMB, liabilities of 1,167.19 million RMB, and net profit of 131.63 million RMB [2]. - Xinyang Dacarelin: Total assets of 87.87 million RMB, liabilities of 45.28 million RMB, and net profit of 1.02 million RMB [2]. Necessity and Reasonableness of Guarantee - The guarantee is deemed necessary to meet the operational needs of the subsidiaries and aligns with the company's overall interests and development strategy [4]. - The subsidiaries are reported to have stable financial conditions and good creditworthiness, indicating their ability to repay the debts [4]. Cumulative External Guarantee - As of the announcement date, the total amount of guarantees signed after the 2024 annual general meeting authorization is 600 million RMB, accounting for 6.95% of the company's latest audited net assets [5]. - There are no overdue external guarantees or guarantees involving litigation reported [5].

证券代码：603233 证券简称：大参林 公告编号：2025-034 大参林医药集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 投资者可于 2025 年 5 月 29 日(星期四)至 6 月 5 日(星期四)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 DSL1999@dslyy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 大参林医药集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日 发布公司 2024 年年度报告及 2025 年第一季度报告，为便于广大投资者更全面深 入地了解公司 2024 年度及 2025 年第一季度的经营情况及财务状况，公司计划于 2025 年 6 月 6 日下午 15:00-16:00 举行 2024 年度暨 2025 年第一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以视频直播和网络互动形式召开，公司将针对 ...